TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies

Acquisition target has established proof of concept data demonstrating the therapeutic potential for the treatment of multiple solid tumors EDINBURGH, Scotland, May 6, 2024 /PRNewswire/ — TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the execution of a […]

May 6, 2024